Merck’s Keytruda (pembrolizumab) in Combination with Inlyta (axitinib) Receives European Commission’s Approval as a 1L Therapy for Advanced Renal Cell Carcinoma

 Merck’s Keytruda (pembrolizumab) in Combination with Inlyta (axitinib) Receives European Commission’s Approval as a 1L Therapy for Advanced Renal Cell Carcinoma

Merck To Acquire Tilos Therapeutics for ~ $773M

Shots:

  • The approval is based on P-III KEYNOTE-426 study assessing Keytruda (200mg) + Inlyta (5mg) vs Sunitinib (50mg) in 861 patients in a ratio (1:1) with advanced RCC regardless of PD-L1 tumor expression and IMDC risk group
  • The P-III KEYNOTE-426 study results: improvement in OS, 47% reduction in risk of death, m-PFS (15.1 vs 11.0 mos.); ORR (59% vs 36%); CRR (6% vs 2%); PRR (53% vs 34%). The approval allows marketing of Keytruda dual regimen in all 28 EU member states + Iceland, Lichtenstein and Norway
  • KEYTRUDA is an anti-PD-1 therapy, act blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells and is the first anti-PD-1 therapy to be approved in EU as combination therapy for RCC across all IMDC risk groups

Click here to­ read full press release/ article | Ref: Business Wire | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post